A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.

MLA

Lester, Jason F., et al. “A Single Centre Phase II Trial to Assess the Immunological Activity of TroVax® plus Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma - the SKOPOS Trial.” Oncoimmunology, vol. 7, no. 12, Sept. 2018, p. e1457597. EBSCOhost, https://doi.org/10.1080/2162402X.2018.1457597.

APA

Lester, J. F., Casbard, A. C., Al-Taei, S., Harrop, R., Katona, L., Attanoos, R. L., Tabi, Z., & Griffiths, G. O. (2018). A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial. Oncoimmunology, 7(12), e1457597. https://doi.org/10.1080/2162402X.2018.1457597

Chicago

Lester, Jason F, Angela C Casbard, Saly Al-Taei, Richard Harrop, Lajos Katona, Richard L Attanoos, Zsuzsanna Tabi, and Gareth O Griffiths. 2018. “A Single Centre Phase II Trial to Assess the Immunological Activity of TroVax® plus Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma - the SKOPOS Trial.” Oncoimmunology 7 (12): e1457597. doi:10.1080/2162402X.2018.1457597.